Novo Nordisk obesity drug results underwhelm investors

[Northerner]

Overweight and obese diabetes patients given high doses of Novo Nordisk's drug liraglutide achieved 6 percent weight loss in a clinical trial, only slightly above the loss seen in those on a lower dose.

The Danish group, the world's biggest insulin producer, said on Monday it was pleased with the results. But investors worried about where it left Novo's strategy for a premium-priced high-dose obesity treatment and shares in the company fell 4 percent.

http://www.reuters.com/article/2013/03/18/us-novonordisk-idUSBRE92H0EY20130318

 

[Vicsetter]

Victoza(liraglutide) has done nothing for me in terms of weight loss.
1.8 is the highest dose recommended in the patient leaflet and increases the risk of nausea, vomiting etc and pancreatitis is listed as a possible side effect.